EBITDA: Income before interest, taxes, depreciation and amortization.
Acrivon Therapeutics, Inc. (ACRV) had EBITDA of $-91.97M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-80.56M |
|
-- |
|
-- |
|
$89.20M |
|
$-89.20M |
|
$8.64M |
|
$-80.56M |
|
$-80.56M |
|
$-80.56M |
|
$-80.56M |
|
$-80.56M |
|
$-80.56M |
|
$-89.20M |
|
|
EBITDA |
$-91.97M |
33.79M |
|
33.79M |
|
$-2.38 |
|
$-2.38 |
|
| Balance Sheet Financials | |
$181.63M |
|
$4.47M |
|
$14.96M |
|
$196.59M |
|
$17.21M |
|
-- |
|
$2.59M |
|
$19.80M |
|
$176.79M |
|
$176.79M |
|
$176.79M |
|
31.23M |
|
| Cash Flow Statement Financials | |
$-65.67M |
|
$-51.77M |
|
$121.03M |
|
$36.43M |
|
$40.02M |
|
$3.59M |
|
$14.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.55 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-68.44M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-45.57% |
|
-45.57% |
|
-40.98% |
|
-45.57% |
|
$5.66 |
|
$-2.03 |
|
$-1.94 |
|